Greg Merril is the founder of Adaptive Phage Therapeutics. Adaptive Phage Therapeutics has raised $92M in total funding. Latest round: Series B.
Greg Merril is the CEO of Adaptive Phage Therapeutics, a clinical-stage biotech company focused on developing therapies to treat multi-drug resistant infections. The company utilizes a therapeutic approach called PhageBank, which is a library of bacteriophage designed to kill bacteria. This approach aims to provide an adaptive and evergreen solution to the ongoing evolution of antibiotic resistance.
Full founder directory · Investor directory · Company funding database · Fundraising library